Search Results for "methylphenidate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for methylphenidate. Results 41 to 43 of 43 total matches.

Lisdexamfetamine dimesylate (Vyvanse) for ADHD

   
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007  (Issue 1265)
potential than amphetamine itself for abuse, diversion or overdose toxicity. 1,2 Like methylphenidate ...
Lisdexamfetamine dimesylate (Vyvanse - Shire), a prodrug in which d-amphetamine is covalently bonded to L-lysine, has been approved by the FDA for treatment of attention-deficit/hyperactivity disorder (ADHD) in children 6-12 years old. It was designed to have less potential than amphetamine itself for abuse, diversion or overdose toxicity. Like methylphenidate and amphetamines, lisdexamfetamine is a Schedule II controlled substance.
Med Lett Drugs Ther. 2007 Jul 16;49(1265):58-9 |  Show IntroductionHide Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
together, and the risk appears to be low iConcomitant use of methylphenidate, amphetamines ...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 |  Show IntroductionHide Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021  (Issue 1618)
to be low. Concomitant use of methylphenidate, amphetamines, or sympathomimetic amines ...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 |  Show IntroductionHide Introduction